Expertise in
25
conditions

Daobin B. Zhou

Peking Union Medical College Hospital, Peking Union Medical College, 
Beijing, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
25
conditions
Peking Union Medical College Hospital, Peking Union Medical College, 
Beijing, CN 

Overview

Daobin Zhou practices practicing medicine in Beijing, China.

Zhou is highly rated in 25 conditions, according to our data. Their clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Splenectomy.

They are actively involved in clinical research, co-authoring 349 peer reviewed articles and participating in 2 clinical trials.

Locations

Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

349 Total Publications

Optimized interpretation of p53 immunohistochemistry for prediction of TP53 mutations and patient survival in DLBCL.
Optimized interpretation of p53 immunohistochemistry for prediction of TP53 mutations and patient survival in DLBCL.
Journal: Clinical and experimental medicine
Published: March 10, 2026

Frequently Asked Questions about Daobin B. Zhou

Is Daobin B. Zhou a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Daobin B. Zhou is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Daobin B. Zhou participate in research or clinical trials?

Yes. Daobin B. Zhou has published 349 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Daobin B. Zhou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile